Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer.
暂无分享,去创建一个
Philippe Lambin | Dirk De Ruysscher | Liesbeth Boersma | Angela van Baardwijk | P. Lambin | L. Boersma | D. de Ruysscher | A. Dingemans | G. Bootsma | W. Geraedts | C. Pitz | M. Ollers | A. V. van Baardwijk | J. Borger | Stofferinus Wanders | Michel Ollers | Jacques Borger | Gerben Bootsma | Cordula Pitz | Ragnar Lunde | Wiel Geraedts | S. Wanders | Anne-Marie C Dingemans | R. Lunde | Wiel Geraedts
[1] K. Ang,et al. Clinical radiation doses for spinal cord: the 1998 international questionnaire. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] Shipeng Yu,et al. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] R. Mohan,et al. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] Philippe Lambin,et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. , 2006, Cancer treatment reviews.
[5] Robert D Timmerman,et al. The North American Experience with Stereotactic Body Radiation Therapy in Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] J. López-Picazo,et al. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] R K ten Haken,et al. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. , 1990, International journal of radiation oncology, biology, physics.
[8] T. Lawrence,et al. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. , 2008, Cancer control : journal of the Moffitt Cancer Center.
[9] M. Socinski,et al. Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium , 2004 .
[10] J. Ferlay,et al. Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] W. De Neve,et al. Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. , 2008, The oncologist.
[12] P. Jenkins,et al. A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] Ladislav Pecen,et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. , 2004, Lung cancer.
[14] Suresh Senan,et al. Radiotherapy for lung cancer: clinical impact of recent technical advances. , 2009, Lung cancer.
[15] J. Daurès,et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Curran,et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs): A1-05 , 2007 .
[17] N. O'Rourke,et al. Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.
[18] Maria Werner-Wasik,et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[19] K. Kubota,et al. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Ursula Nestle,et al. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] R. Arriagada,et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.
[22] T E Schultheiss,et al. Radiation response of the central nervous system. , 1995, International journal of radiation oncology, biology, physics.
[23] N. Saijo,et al. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Suresh Senan,et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] F. Würschmidt,et al. Continuous hyperfractionated accelerated therapy in non-small-cell lung cancer , 1997, The Lancet.
[26] H. Groen,et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Michael Lock,et al. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[28] W. Curran. Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer. , 2003, Oncology.
[29] P. Maguire,et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P Lambin,et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types , 2008, British Journal of Cancer.
[31] P. Lambin,et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[32] R K Ten Haken,et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.
[33] P. Lambin,et al. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. , 2008, International journal of radiation oncology, biology, physics.
[34] N. Hanna. Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group , 2008 .
[35] Jose Belderbos,et al. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[36] P. Lambin,et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.
[37] M. Socinski,et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] G. Steel,et al. Basic Clinical Radiobiology , 1997 .
[39] H. Groen,et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] A Harvey,et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[41] John D Fenwick,et al. A challenge to traditional radiation oncology. , 2004, International journal of radiation oncology, biology, physics.
[42] J D Fenwick,et al. Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).
[43] Randall K Ten Haken,et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.
[44] Joseph O Deasy,et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. , 2007, International journal of radiation oncology, biology, physics.
[45] W. Scott,et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.
[46] Mike Partridge,et al. Improvement in tumour control probability with active breathing control and dose escalation: a modelling study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[47] S. Dische,et al. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).
[48] S Kramer,et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non‐oat‐cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group , 1980, Cancer.
[49] Randall K Ten Haken,et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. , 2009, International journal of radiation oncology, biology, physics.
[50] W. Curran,et al. Concomitant Radio-chemotherapy (CT-RT) versus Sequential CT-RT In Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): A Meta-Analysis Using Individual Patient Data (IPD) From Randomised Clinical Trials (RCTs) , 2007 .
[51] H Jaradat,et al. Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study , 2008, Technology in cancer research & treatment.
[52] Lawrence B Marks,et al. Radiation-induced narrowing of the tracheobronchial tree: an in-depth analysis. , 2006, Lung cancer.
[53] R. T. Ten Haken,et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. , 2005, International journal of radiation oncology, biology, physics.
[54] J. Lebesque,et al. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.
[55] Philippe Lambin,et al. Routine individualised patient dosimetry using electronic portal imaging devices. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.